Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin

Journal of Magnetic Resonance Imaging, 05/03/2012

Dynamic contrast–enhanced (DCE) magnetic resonance imaging (MRI) enables a functional analysis of the treatment response of nonsmall–cell lung cancer (NSCLC). MRI parametric histogram has the potential to predict early treatment response of combined bevacizumab, gemcitabine, and cisplatin.

Print Article Summary Cat 2 CME Report